Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease

Catherine A. Leitch, Julie Ahlrichs, Cheryl Karn, Scott Denne

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Dexamethasone is commonly administered to ventilator-dependent preterm infants with chronic lung disease. Infants receiving dexamethasone therapy frequently exhibit decreased rates of weight gain. The purpose of this investigation was to determine whether decreased growth in infants receiving dexamethasone therapy is caused by increased energy expenditure. Twelve infants were studied: 6 received dexamethasone treatment at 2 wk of age and crossed over to receive placebo treatment at 4 wk; the treatment order was reversed in the other 6 infants. The doubly labeled water method was used to determine energy expenditure for a 1-wk period during each treatment phase. The rate of weight gain during dexamethasone treatment was 6.5 ±10.6 and 20.0 ± 5.7 g/kg/d during placebo treatment. Energy expenditure was 93.1 ± 34.6 kcal/kg/d during dexamethasone treatment and 88.3 ± 37.1 kcal/kg/d during placebo treatment. Energy intake was 119.2 ± 29.0 kcal/kg/d during dexamethasone treatment and 113.8 ± 23.7 kcal/kg/d during placebo treatment. The difference between intake and expenditure, or the energy available for growth, was 26.2 ± 36.8 kcal/kg/d during dexamethasone treatment and 25.5 ± 37.4 kcal/kg/d during placebo treatment. No significant differences were found in energy expenditure or energy intake between the treatment phases. The reduced growth seen in infants receiving dexamethasone treatment cannot be explained by increased energy expenditure or decreased energy intake, but may be due to differences in the composition of newly accreted tissue.

Original languageEnglish
Pages (from-to)109-113
Number of pages5
JournalPediatric Research
Volume46
Issue number1
StatePublished - Jul 1999

Fingerprint

Energy Intake
Energy Metabolism
Dexamethasone
Lung Diseases
Chronic Disease
Therapeutics
Placebos
Weight Gain
Growth
Mechanical Ventilators
Premature Infants

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. / Leitch, Catherine A.; Ahlrichs, Julie; Karn, Cheryl; Denne, Scott.

In: Pediatric Research, Vol. 46, No. 1, 07.1999, p. 109-113.

Research output: Contribution to journalArticle

Leitch, Catherine A. ; Ahlrichs, Julie ; Karn, Cheryl ; Denne, Scott. / Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. In: Pediatric Research. 1999 ; Vol. 46, No. 1. pp. 109-113.
@article{00054bccadd24b16a2c790c7b49e9fd2,
title = "Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease",
abstract = "Dexamethasone is commonly administered to ventilator-dependent preterm infants with chronic lung disease. Infants receiving dexamethasone therapy frequently exhibit decreased rates of weight gain. The purpose of this investigation was to determine whether decreased growth in infants receiving dexamethasone therapy is caused by increased energy expenditure. Twelve infants were studied: 6 received dexamethasone treatment at 2 wk of age and crossed over to receive placebo treatment at 4 wk; the treatment order was reversed in the other 6 infants. The doubly labeled water method was used to determine energy expenditure for a 1-wk period during each treatment phase. The rate of weight gain during dexamethasone treatment was 6.5 ±10.6 and 20.0 ± 5.7 g/kg/d during placebo treatment. Energy expenditure was 93.1 ± 34.6 kcal/kg/d during dexamethasone treatment and 88.3 ± 37.1 kcal/kg/d during placebo treatment. Energy intake was 119.2 ± 29.0 kcal/kg/d during dexamethasone treatment and 113.8 ± 23.7 kcal/kg/d during placebo treatment. The difference between intake and expenditure, or the energy available for growth, was 26.2 ± 36.8 kcal/kg/d during dexamethasone treatment and 25.5 ± 37.4 kcal/kg/d during placebo treatment. No significant differences were found in energy expenditure or energy intake between the treatment phases. The reduced growth seen in infants receiving dexamethasone treatment cannot be explained by increased energy expenditure or decreased energy intake, but may be due to differences in the composition of newly accreted tissue.",
author = "Leitch, {Catherine A.} and Julie Ahlrichs and Cheryl Karn and Scott Denne",
year = "1999",
month = "7",
language = "English",
volume = "46",
pages = "109--113",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease

AU - Leitch, Catherine A.

AU - Ahlrichs, Julie

AU - Karn, Cheryl

AU - Denne, Scott

PY - 1999/7

Y1 - 1999/7

N2 - Dexamethasone is commonly administered to ventilator-dependent preterm infants with chronic lung disease. Infants receiving dexamethasone therapy frequently exhibit decreased rates of weight gain. The purpose of this investigation was to determine whether decreased growth in infants receiving dexamethasone therapy is caused by increased energy expenditure. Twelve infants were studied: 6 received dexamethasone treatment at 2 wk of age and crossed over to receive placebo treatment at 4 wk; the treatment order was reversed in the other 6 infants. The doubly labeled water method was used to determine energy expenditure for a 1-wk period during each treatment phase. The rate of weight gain during dexamethasone treatment was 6.5 ±10.6 and 20.0 ± 5.7 g/kg/d during placebo treatment. Energy expenditure was 93.1 ± 34.6 kcal/kg/d during dexamethasone treatment and 88.3 ± 37.1 kcal/kg/d during placebo treatment. Energy intake was 119.2 ± 29.0 kcal/kg/d during dexamethasone treatment and 113.8 ± 23.7 kcal/kg/d during placebo treatment. The difference between intake and expenditure, or the energy available for growth, was 26.2 ± 36.8 kcal/kg/d during dexamethasone treatment and 25.5 ± 37.4 kcal/kg/d during placebo treatment. No significant differences were found in energy expenditure or energy intake between the treatment phases. The reduced growth seen in infants receiving dexamethasone treatment cannot be explained by increased energy expenditure or decreased energy intake, but may be due to differences in the composition of newly accreted tissue.

AB - Dexamethasone is commonly administered to ventilator-dependent preterm infants with chronic lung disease. Infants receiving dexamethasone therapy frequently exhibit decreased rates of weight gain. The purpose of this investigation was to determine whether decreased growth in infants receiving dexamethasone therapy is caused by increased energy expenditure. Twelve infants were studied: 6 received dexamethasone treatment at 2 wk of age and crossed over to receive placebo treatment at 4 wk; the treatment order was reversed in the other 6 infants. The doubly labeled water method was used to determine energy expenditure for a 1-wk period during each treatment phase. The rate of weight gain during dexamethasone treatment was 6.5 ±10.6 and 20.0 ± 5.7 g/kg/d during placebo treatment. Energy expenditure was 93.1 ± 34.6 kcal/kg/d during dexamethasone treatment and 88.3 ± 37.1 kcal/kg/d during placebo treatment. Energy intake was 119.2 ± 29.0 kcal/kg/d during dexamethasone treatment and 113.8 ± 23.7 kcal/kg/d during placebo treatment. The difference between intake and expenditure, or the energy available for growth, was 26.2 ± 36.8 kcal/kg/d during dexamethasone treatment and 25.5 ± 37.4 kcal/kg/d during placebo treatment. No significant differences were found in energy expenditure or energy intake between the treatment phases. The reduced growth seen in infants receiving dexamethasone treatment cannot be explained by increased energy expenditure or decreased energy intake, but may be due to differences in the composition of newly accreted tissue.

UR - http://www.scopus.com/inward/record.url?scp=0033020060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033020060&partnerID=8YFLogxK

M3 - Article

C2 - 10400143

AN - SCOPUS:0033020060

VL - 46

SP - 109

EP - 113

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 1

ER -